Clinical Trials

LinkedIn
Facebook

The INTERCEPT Clinical Trials

The INTERCEPT project aims to verify and clinically validate a panel of biomarkers and build a blood risk score through two clinical trials spanning seven European countries that can identify individuals with a high risk of developing Crohn’s disease within five years after initial evaluation.

The PREDICT-CD Trial

The trial will recruit 10,000 healthy FDRs of individuals with Crohn’s disease from seven European countries:

  • Portugal
  • Spain
  • France
  • Italy
  • The Netherlands
  • Poland
  • Sweden


Through samples of serum - the fluid and solvent component of blood – provided by participants, the trial will further validate the biomarkers and risk score.

From this group, 80 FDRs with the highest risk of developing Crohn’s disease will be invited to take part in an innovative trial aimed at preventing full-blown disease development through an established and highly effective medical treatment.

Eligibility Requirements for the Trial

You must be a first-degree relative of a patient with an established diagnosis of Crohn’s disease.
Male or female between 16 and 35 years of age able to assent or consent.
Able to understand information provided and give written informed assent or consent for the study.

Exclusion Criteria

Prior diagnosis of Inflammatory Bowel Disease (IBD).
Any legal or medical condition that limits the information and participation in the study.
Inability to verify Crohn’s disease diagnosis in a first-degree relative.
Unwilling or unable to provide informed written consent.
Unwilling or unable to provide serum.

Frequently asked questions:

There are many questions associated with taking part in a clinical trial. In order to answer these, kindly look through the following pamphlet on the PREDICT-CD Trial.


Download the pamphlet